Catalyst overview
Research summary
This catalyst tracks a Phase 1a data readout for ANX1502 in Cold agglutinin disease. The expected timing is based on the latest available company guidance and may change.
12/20/23- Ph1 results from SAD & MAD study. 3/3/25- Ongoing POC trial expanded dataset to include up to seven patients. Q2 '25- Update on POC trial by YE 2025. 11/10/25:- CAD POC study completion in 2026. 01/12/26:- CAD POC trial PK/PD evaluation ongoing; update and proof-of-concept data anticipated during 2026. 03/30/26:- CAD POC study enrollment ongoing; dosing timing adjusted around food; update on POC results anticipated in 2026. 05/07/26:- Reiterated CAD POC trial ongoing with data and update anticipated in 2026. 08/12/26:- CAD POC dosing completed. POC trial update is anticipated in Fall 2026.
Verification
Confirm timing and program details against the company announcement or filing.